Bladder Cancer - Results from #100

A Hypothesis-Generating Analysis on the Role of TERT Promoter Mutation in Advanced Urothelial Carcinoma Treated with Immunotherapy - Beyond the Abstract November 3, 2022

International Consensus Guidelines for Adjuvant Radiation Therapy for Bladder Cancer After Radical Cystectomy: Update From an IBIS Workgroup - Beyond the Abstract November 2, 2022

Novel Intravesical Bacterial Immunotherapy Induces Rejection of BCG-Unresponsive Established Bladder Tumors - Beyond the Abstract October 10, 2022

Immune Mechanisms and Molecular Therapeutic Strategies to Enhance Immunotherapy in Non-Muscle Invasive Bladder Cancer - Beyond the Abstract September 20, 2022

Phase II Trial of CV301 Vaccine Combined with Atezolizumab in Advanced Urothelial Carcinoma - Beyond the Abstract September 7, 2022

Machine Learning Decision Support Model for Radical Cystectomy Discharge Planning - Beyond the Abstract August 30, 2022

En Bloc Versus Conventional Transurethral Resection of Bladder Tumors: A Single-center Prospective Randomized Non inferiority Trial - Beyond the Abstract August 3, 2022

C-Reactive Protein Flare Predicts Response to Anti-PD-(L)1 Immune Checkpoint Blockade in Metastatic Urothelial Carcinoma - Beyond the Abstract July 27, 2022

Treatment Trends for Muscle-Invasive Bladder Cancer in Germany from 2006 to 2019 - Beyond the Abstract July 26, 2022

The Learning Curve in Bladder MRI Using VI-RADS Assessment Score During an Interactive Dedicated Training Program - Beyond the Abstract July 20, 2022

Systemic Therapy Issues: Immunotherapy in Nonmetastatic Urothelial Cancer - Beyond the Abstract July 19, 2022

What Did We Learn from ESMO 2021, and What’s Next? A Peer-Reviewed Podcast with a Patient Advocate and Physician - Beyond the Abstract July 12, 2022

Adjuvant Chemotherapy Versus Observation Following Radical Cystectomy for Locally Advanced Urothelial Carcinoma of the Bladder - Beyond the Abstract June 30, 2022

Combined miRNA and SERS Urine Liquid Biopsy for the Point-of-Care Diagnosis and Molecular Stratification of Bladder Cancer - Beyond the Abstract June 23, 2022

Contemporary Staging for Muscle-Invasive Bladder Cancer: Accuracy and Limitations - Beyond the Abstract June 22, 2022

Characterizing Molecular Subtypes of High-Risk Non-Muscle-Invasive Bladder Cancer in African American Patients - Beyond the Abstract June 21, 2022

A Phase 1/2 Single-arm Clinical Trial of Recombinant Bacillus Calmette-Guérin (BCG) VPM1002BC Immunotherapy in Non-muscle-invasive Bladder Cancer Recurrence After Conventional BCG Therapy: SAKK 06/14 - Beyond the Abstract June 13, 2022

Culture of Bladder Cancer Organoids as Precision Medicine Tools - Beyond the Abstract May 3, 2022

Immune Checkpoints Inhibitors in the Management of High-Risk Non-Muscle-Invasive Bladder Cancer. A Scoping Review - Beyond the Abstract April 27, 2022

Diagnostic Accuracy of Vesical Imaging-Reporting and Data System (VI-RADS) in Suspected Muscle Invasive Bladder Cancer: A Systematic Review and Diagnostic Meta-Analysis - Beyond the Abstract April 26, 2022

Page 6 of 24